Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 10/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.37 |
| ▸ | XDH | P47989 | 2/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18052605 | 0.79 | XDH (0.37) | XDH | |
| Hydrochloric Acid SCHEMBL16611599 | 0.78 | XDH (0.37) | XDH | |
| SCHEMBL16610802 | 0.76 | SRC (0.41) | XDH | |
| SCHEMBL16611419 | 0.76 | XDH (0.39) | XDH | |
| SCHEMBL16611598 | 0.75 | XDH (0.38) | XDH | |
| SCHEMBL16611405 | 0.75 | BMPR1A (0.38) | XDHPIK3CDRET | |
| SCHEMBL16611359 | 0.75 | KDM5A (0.42) | XDH | |
| SCHEMBL16611032 | 0.74 | BMPR1A (0.37) | XDH | |
| SCHEMBL16610735 | 0.74 | KDM5A (0.42) | XDHRET | |
| SCHEMBL16610767 | 0.73 | MTOR (0.36) | XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9371320-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857400-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | ATR 1014/4885CYP4F2 4387/4885CYP4A11 1900/4885 |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | ATR 1014/4885CYP4F2 4387/4885CYP4A11 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.